You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

~ Buy the COSELA (trilaciclib dihydrochloride) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR COSELA

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for COSELA

Subscribe to access the full database, or Try a Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04799249 ↗	Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)	Recruiting	G1 Therapeutics, Inc.	Phase 3	2021-04-15	This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of trilaciclib versus placebo administered prior to gemcitabine and carboplatin in patients receiving first- or second-line treatment for locally advanced unresectable/metastatic TNBC.
NCT04863248 ↗	Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)	Recruiting	G1 Therapeutics, Inc.	Phase 2	2021-04-16	This is a randomized, double-blind, placebo-controlled, global, multicenter, Phase 2 trial evaluating the effect of trilaciclib on overall survival when administered prior to docetaxel in patients with mNSCLC treated in the 2nd or 3rd line setting.
NCT04887831 ↗	Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab	Recruiting	G1 Therapeutics, Inc.	Phase 2	2021-06-04	This is a Phase 2, multicenter, randomized, open-label study evaluating the safety and efficacy of trilaciclib administered with platinum-based chemotherapy followed by trilaciclib administered with avelumab maintenance therapy compared with platinum-based chemotherapy followed by avelumab maintenance therapy in patients receiving first-line treatment for advanced/metastatic bladder cancer.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for COSELA

Condition Name

Chart
Table

Condition Name for COSELA
Intervention	Trials
Metastatic Non-Small Cell Lung Cancer	1
Myelosuppression Adult	1
NSCLC	1
TNBC - Triple-Negative Breast Cancer	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for COSELA
Intervention	Trials
Carcinoma, Transitional Cell	1
Carcinoma	1
Lung Neoplasms	1
Carcinoma, Non-Small-Cell Lung	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for COSELA

Trials by Country

Map
Table

Trials by Country for COSELA
Location	Trials
United States	32
Ukraine	4
Poland	3
Georgia	2
Spain	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for COSELA
Location	Trials
Texas	3
California	3
Florida	3
Tennessee	2
Pennsylvania	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for COSELA

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for COSELA
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for COSELA
Clinical Trial Phase	Trials
Recruiting	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for COSELA

Sponsor Name

Chart
Table

Sponsor Name for COSELA
Sponsor	Trials
G1 Therapeutics, Inc.	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for COSELA
Sponsor	Trials
Industry	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.